Open AccessApplication of an iPSC‐Derived Organoid Model for Localized Scleroderma Therapy (Adv. Sci. 16/2022)
Author(s) -
Ma Jie,
Li Wei,
Cao Ruiyuan,
Gao Dunqin,
Zhang Qiyu,
Li Xiao,
Li Biyou,
Lv Luye,
Li Mansheng,
Jiang Junyi,
Wang Yujie,
Li Jun,
Wu Zhihong,
Zhu Yunping,
Zhong Wu,
Zhang Shuyang,
Leng Ling
Publication year - 2022
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202270104
Subject(s) - organoid , induced pluripotent stem cell , epidermis (zoology) , regeneration (biology) , regenerative medicine , mesenchymal stem cell , scleroderma (fungus) , fibrosis , medicine , disfigurement , pathology , microbiology and biotechnology , stem cell , anatomy , biology , surgery , embryonic stem cell , biochemistry , inoculation , gene
Localized Scleroderma Therapy Human‐induced pluripotent stem cell (hiPSC)‐derived epithelial and mesenchymal (EM) organoids can be used to investigate the therapeutic potential for the recovery of localized scleroderma (LoS) associated phenotypes and skin‐associated functions. In article number 2106075, Wu Zhong, Shuyang Zhang, Ling Leng, and co‐workers, establish an experimental EM organoid model from hiPSC to significantly reduce the degree of skin fibrosis and inflammation. Most importantly, it promotes the regeneration of epidermis and their appendages, providing a new therapeutic alternative for patients suffering from disfigurement and skin function defects caused by LoS.